Here's a familiar story in biotech: a big, expensive phase 3 trial doesn't hit its primary goal. The latest company to get that news is Roche Holdings AG (RHHBY), which announced Monday that its persevERA breast cancer study came up short.

The trial was testing a drug called giredestrant, combined with another therapy called palbociclib, in patients with a specific type of advanced breast cancer. The goal was to show it worked better than the current standard combo of letrozole and palbociclib at keeping the cancer from getting worse. It didn't. The improvement wasn't statistically significant.

Now, before you write the whole thing off, there's a bit of nuance here. The company says the study did show a "numerical improvement." That's biotech-speak for "the numbers looked better, just not enough to pass the strict statistical test we set." Think of it like a student who improved their grade from a C to a B-, but the class required a solid B to pass. They're closer, but not there yet.

On the safety side, there were no nasty surprises. The side effects were what you'd expect from these kinds of drugs and were considered manageable.

So, what does Roche do now? They're not throwing in the towel. "We believe there is a path forward for combining giredestrant with a CDK4/6 inhibitor in the adjuvant setting, and we are conducting further studies," said Levi Garraway, Roche's Chief Medical Officer. He pointed to other trials, named evERA and lidERA, which showed positive results. "The efficacy demonstrated in evERA and lidERA provides clear validation of the clinical activity of giredestrant and reinforces the strength of our expanding clinical development programme."

In other words, the company is saying: "Okay, this one specific late-stage trial in advanced cancer didn't work out as hoped, but we have other shots on goal." The evERA trial was actually the first positive phase 3 result for giredestrant. The scientific thinking behind the lidERA trial was backed up by earlier results too.

And there's more coming. The persevERA trial was just the first of two big phase 3 studies in this first-line treatment setting. The next one, called pionERA, is looking at giredestrant combined with a different type of inhibitor for a slightly different patient group—those whose cancer has become resistant to endocrine therapy. We won't know how that one turns out until 2027.

Meanwhile, the regulatory wheels are still turning. The U.S. Food and Drug Administration (FDA) recently accepted a New Drug Application for giredestrant based on the positive evERA data. They've set a decision date for December 18 of this year.

Investors, however, reacted to the immediate news. Shares of Roche fell as much as 5% in early trading in Zurich. The company's main listing is on the SIX Swiss Exchange under the ticker ROG, but it also trades over-the-counter in the U.S. as RHHBF and RHHBY.

This isn't the only piece of disappointing clinical news for Roche lately. Just last week, data came out for an experimental obesity drug it's developing with Zealand Pharma. Results showed it led to up to 10.7% weight loss, which, while not nothing, lags behind the blockbuster treatments from Novo Nordisk A/S (NVO) and Eli Lilly and Co. (LLY). So, for Roche, it's been a bit of a rough patch in the clinic.

The story of giredestrant isn't over. One trial missed, but others have succeeded, and more data is on the horizon. For now, though, it's a setback in a highly competitive field, and the market is treating it as such.